How many insider trades does FilingIQ track for KPTI?

FilingIQ tracks 733 Form 4 insider transactions for KPTI (Karyopharm Therapeutics Inc.), covering filings from Dec 1, 2014 onwards. 8 of those were filed in the last 90 days.

Are KPTI insiders net buyers or net sellers?

Across the full Form 4 history for KPTI, 10 transactions (1%) were open-market purchases and 399 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KPTI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KPTI in?

Karyopharm Therapeutics Inc. (KPTI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $194.26M.

KPTI insider trading

NasdaqGS Healthcare

Karyopharm Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

733

Last 90 days

Buys / sells

1% / 54%

Market cap

$194.26M

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Company website: www.karyopharm.com

KPTI insider activity at a glance

FilingIQ has scored 733 insider transactions for KPTI since Dec 1, 2014. The most recent filing in our index is dated Apr 21, 2026.

Across the full history, 10 open-market purchases and 399 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KPTI insider trades is 51.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KPTI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding KPTI

Opaleye Management Inc.

$6.84M · 0.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for KPTI?: FilingIQ tracks 733 Form 4 insider transactions for KPTI (Karyopharm Therapeutics Inc.), covering filings from Dec 1, 2014 onwards. 8 of those were filed in the last 90 days.
Are KPTI insiders net buyers or net sellers?: Across the full Form 4 history for KPTI, 10 transactions (1%) were open-market purchases and 399 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KPTI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KPTI in?: Karyopharm Therapeutics Inc. (KPTI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $194.26M.

Methodology & sources

Every KPTI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.